English  |  正體中文  |  简体中文  |  总笔数 :2853327  
造访人次 :  45048987    在线人数 :  1674
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"qin s"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 36-45 / 74 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2021-08-31T06:29:30Z Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:20Z Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S.
臺大學術典藏 2021-08-31T06:29:18Z Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y.
臺大學術典藏 2021-08-31T06:29:17Z Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators
臺大學術典藏 2021-08-31T06:29:17Z IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S.
臺大學術典藏 2021-08-31T06:29:13Z Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression Ryoo B.-Y.; ANN-LII CHENG; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S.
臺大學術典藏 2021-08-11T03:46:38Z A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏 2021-07-03T03:34:45Z Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W.
臺大學術典藏 2021-07-03T03:34:40Z Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma Yeo W.; PEI-JER CHEN; Furuse J.; Han K.-H.; Hsu C.; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L.
臺大學術典藏 2021-07-03T03:33:57Z Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial Cainap C.; Qin S.; Huang W.-T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.-K.; PEI-JER CHEN; Toh H.-C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S.

显示项目 36-45 / 74 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目